PFIZER INC（PFE）の決算・業績分析
PFIZER INCの2025年有価証券報告書をAI分析。売上高$62.6B(-1.6%)。Health Care。
目次
PFIZER INCの2025年度 業績サマリー
PFIZER INC（証券コード: PFE）の2025年度決算・業績分析。売上高は$62.6B（前年比-1.6%）。純利益は$7.8B（前年比-3.2%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
PFIZER INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Pfizer Inc. (PFE) achieved a 37.4% YoY revenue increase to $101.2B (XBRL), driven by strong performance in biopharmaceutical products.
- Net income surged 42.7% YoY to $31.4B (XBRL), with a net margin of 31.0% and ROE of 35.2% (XBRL).
- Free cash flow (FCF) reached $26.0B (XBRL), reflecting robust operating cash flow ($29.3B) and disciplined CapEx ($3.2B).
- Despite a 5-year net income CAGR of -28.3% (XBRL), FY2024 results show a sharp turnaround with record profitability.
PFIZER INCの売上高変化の要因
- •Revenue grew 37.4% YoY to $101.2B (XBRL), jumping from $73.6B in FY2023. The 5-year revenue CAGR is 7.8% (XBRL), though net income CAGR is -28.3% (XBRL). No segment-specific revenue data is available in the provided XBRL data (N/A). The historical time series shows a significant acceleration in revenue growth, with FY2024 revenue nearly 36% higher than FY2023.
PFIZER INCの営業利益変化の要因
- •Operating income rose to $41.7B (XBRL), with an operating margin of 41.2% (XBRL). EBITDA reached $46.8B (46.2% margin) (XBRL), and net income increased 42.7% YoY to $31.4B (31.0% margin) (XBRL). Net income in FY2023 was $22.0B (XBRL), reflecting a significant improvement in FY2024. Gross profit data is not available (N/A).
PFIZER INCの事業リスクと対応
Managed care trends may force rebates or restrict formulary placement, impacting pricing and sales (10-K).
Competitive products, including generic drugs and rivals' innovations, could erode sales or render products obsolete (10-K).
Regulatory/legal risks include changes in fraud/abuse laws and the Inflation Reduction Act (IRA), which introduces public pricing transparency (10-K).
Pricing pressures from the IRA and managed care initiatives may require lower prices or larger rebates (10-K).
Industry consolidation may enhance competitors' advantages and pricing power (10-K).
Gross unrecognized tax benefits of $4.5B are disclosed as a contingent liability (10-K).
PFIZER INCの今後の見通し・業績予想
PFIZER INCの事業内容
Pfizer Inc. is a research-based global biopharmaceutical company generating revenue through the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products (10-K). Key segments include Biopharma (innovative science-based biopharmaceuticals), PC1 (contract development and manufacturing of specialty pharmaceutical ingredients), and Pfizer Ignite (R&D services for biotech companies) (10-K). Competitive advantages include R&D productivity, operational efficiency, and a strong product pipeline (10-K). The acquisition of Seagen (2023) is noted, but no direct competitors are explicitly mentioned (10-K).
PFIZER INCのAI業績分析レポート（2024年度）
Annual Report Analysis: Pfizer Inc. (PFE) FY2024
Highlights
Business Overview
Pfizer Inc. operates as a research-based global biopharmaceutical company, generating revenue through the sale of biopharmaceutical products (10-K). Key segments include Biopharma, PC1, and Pfizer Ignite (10-K). Competitive advantages include R&D productivity, operational efficiency, and a strong product pipeline (10-K). No significant customer concentration or direct competitors are explicitly mentioned (10-K).
Revenue Analysis
Revenue increased 37.4% YoY to $101.2B (XBRL), up from $73.6B in FY2023. The 5-year revenue CAGR is 7.8% (XBRL), but net income CAGR is -28.3% (XBRL). Segment-specific revenue data is not available in the provided XBRL data (N/A).
Profitability Analysis
Operating income rose to $41.7B (XBRL) with a 41.2% operating margin (XBRL). EBITDA reached $46.8B (46.2% margin) (XBRL), and net income increased 42.7% YoY to $31.4B (31.0% margin) (XBRL). Gross profit data is not available (N/A).
Balance Sheet Analysis
Total assets increased to $226.5B (XBRL), with total equity of $89.0B (XBRL). The equity ratio is 39.3% (XBRL), and D/E ratio is 1.54x (XBRL). Net debt is $58.7B (1.2x EBITDA) (XBRL). Cash balances are $2.9B (XBRL), and the current ratio is 0.91x (XBRL).
Cash Flow Analysis
Operating cash flow (OCF) was $29.3B (XBRL), with FCF of $26.0B (XBRL) after $3.2B in CapEx (XBRL). Investing cash flow was -$15.8B (XBRL), and financing cash flow was -$14.8B (XBRL), driven by $9.0B in dividends paid (XBRL) and $2.0B in share repurchases (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) is 79 days (XBRL), with receivables days at 42 days (XBRL), inventory days at 108 days (XBRL), and payables days at 71 days (XBRL).
Risks
Outlook
Management guidance and forward-looking trends are not explicitly detailed in the provided 10-K or XBRL data (N/A).
Health Careの企業一覧
PFIZER INCと同じ「Health Care」セクターの企業